Dexmedetomidine is a highly selective α2-adrenergic receptor agonist used clinically for sedation, hypnosis, analgesia, and sympatholytic effects, particularly in anesthesia and intensive care unit (ICU) sedation. It induces a near-physiological sleep-like state with minimal respiratory depression and strong neuroprotective properties. Due to advances in anesthesiology and sleep medicine, it is increasingly applied in the diagnosis and treatment of sleep disorders. Its sedative-hypnotic effect is mediated via α2 receptors in the locus coeruleus and activation of endogenous sleep-promoting pathways, maintaining patients in non-rapid eye movement (NREM) stage III sleep, during which they remain arousable by verbal or physical stimuli without respiratory depression. Additional effects include anxiolysis, attenuation of stress responses, hemodynamic stabilization, analgesia, inhibition of salivary secretion, anti-shivering, and diuresis. Dexmedetomidine also exhibits synergistic effects when combined with other sedative or analgesic agents, significantly reducing the required doses of those drugs.